Bacterial cultures and empirical antimicrobial therapy for community-acquired secondary peritonitis;Prélèvements microbiologiques et traitements antibiotiques probabilistes des péritonites secondaires communautaires

Journal de Chirurgie

Volumn 144, Issue 6, 2007, Pages 486-491

  Monteiro, M C ^a   Danielou, A ^a   Piemont, Y ^b   Hansmann, Y ^c   Rohr, S ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b HÔPITAL CIVIL   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Antibiotherapy; Peritonitis

Indexed keywords

EID: 38149004888     PISSN: 00217697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-7697(07)79773-9     Document Type: Short Survey

References (25)

1. Wittmann DH. Intra-abdominal infection. World J Surg 1990;14:145-147.
2. Troché G. Pronostic des péritonites. Med Mal Infect. 1995;25:S20-S37.
3. Robert J. Épidémiologie microbienne des péritonites. Réanimation 2004;13:S15-S18.
4. Rotstein OD, Meakins JL. Diagnosis and therapeutic challenges of intra-abdominal infections. World J Surg 1990;14:159-166.
5. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991;214:543-549.
6. Montravers P, Chalfine A, Gauzit R, et al. Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections. Ann Surg 2004;239:409-416.
7. Roehrborn A, Thomas L, Potreck O, et al. The microbiology of postoperative peritonitis. Clin Infect Dis 2001;33:1513-1519.
8. Société Française d'Anesthésie et de Réanimation. Conférence de consensus. Prise en charge des péritonites communautaires. 16 juin 2000. www.sfar.org/pdf/peritonites. pdf
9. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of antiinfective agents for complicated intraabdominal infections. Clin Infect Dis 2003;37:997-1005.
10. Bosscha K, van Vroonhoven TJ, van der Werken C. Surgical management of severe secondary peritonitis. Br J Surg 1999;86:1371-1377.
11. Dupont H. Stratégie antibiotique dans les peritonitis. Réanimation 2004;13:S25-S29.
12. Dougherty SH, Sirinek KR, Schauer PR, et al. Ticarcillin/ clavulanate compared with clindamycin/gentamicin (with or without ampicillin) for the treatment of intra-abdominal infections in pediatric and adult patients. Am Surg 1995;61:297-303.
13. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin + metronidazole to imipenem/cilastin for intraabdominal infections. Ann Surg 1996;223:303-315.
14. Cohn SM, Lipsett PA, Buchman TG, et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2000;232:254-262.
15. Barie PS, Vogel SB, Dellinger EP, et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-Abdominal Infection Study Group. Arch Surg 1997;132:1294-1302.
16. Basoli A, Meli EZ, Mazzocchi P, Speranza V. Imipenem/cilastatin (1,5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. Scand J Infect 1997;29:503-508.
17. Solomkin JS, Yellin AE, Rotstein OD, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003;237:235-245.
18. Société Française d'Anesthésie et de Réanimation. Conférence d'experts. Texte court 2004. Antibiothérapie probabiliste des états septiques graves. www.sfar.org
19. Barrall DT, Kenney PR, Slotman GJ, Burchard KW. Enterococcal bacteremia in surgical patients. Arch Surg 1985;120:57-63.
20. Burnett RJ, Haverstock DC, Dellinger EP, et al.Definition of the role of Enterococcus in intraabdominal infection: analysis of a retrospective randomized trial. Surgery 1995;118:716-721.
21. Sotto A, Lefrant JY, Fabbro-Peray P, et al. Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother 2002;50:569-576.
22. Harbarth S, Uckay I. Are there patients with peritonitis who required empiric therapy for Enterococcus? Eur J Clin Microbiol Infect Dis 2004;23:73-77.
23. Montravers P, Dupont H, Gauzit R, et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006;34:646-652.
24. Dupont H, Paugam-Burtz C, Muller-Serieys C, et al. Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients. Arch Surg 2002;137:1341-1346.
25. Dupont H, Carbon C, Carlet J, Schweich H and the Peritonitis Study Group. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. Antimicrob Agents Chemother 2000;44:2028-2033.